Semax

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is Semax?

Semax is a synthetic heptapeptide analog of ACTH(4-10) — the fragment of adrenocorticotropic hormone (ACTH) responsible for cognitive and neurotrophic effects, stripped of the hormonal segments that drive adrenal cortex activation. The semax peptide was developed at the Institute of Molecular Genetics, Russian Academy of Sciences, with the specific goal of isolating nootropic and neuroprotective activity from full-length ACTH while eliminating cortisol-stimulating properties. Its sequence — Met-Glu-His-Phe-Pro-Gly-Pro — retains the ACTH(4-10) core with a C-terminal Pro-Gly-Pro extension engineered for metabolic stability.

What distinguishes semax from most investigational peptides is its regulatory history: it has been approved in Russia since 2001 as a nootropic and neuroprotective nasal spray, giving it a level of clinical validation that most research peptides lack. Semax nootropic research centres on its ability to upregulate brain-derived neurotrophic factor (BDNF) and activate dopaminergic and serotonergic systems — mechanisms that connect it to synaptic plasticity, learning, memory, and neuroprotection after ischemic injury.

Despite its Russian approval and a growing body of English-language mechanistic research, semax remains unapproved by the FDA and EMA. It occupies an unusual position: more clinically validated than most research peptides, but without the large-scale Western clinical trial data that would establish it in international regulatory frameworks. For context, compounds like BPC-157 and GHK-Cu share investigational neuroprotective profiles through different mechanisms.

Compound Profile

What Does Semax Actually Do?

Semax enhances cognitive function primarily through upregulation of brain-derived neurotrophic factor (semax BDNF). BDNF is the brain’s principal neurotrophin — the protein that drives synaptic plasticity, neuronal survival, and the formation of new synaptic connections that underlie learning and memory. By increasing BDNF and its receptor TrkB in the hippocampus, semax activates the molecular machinery of cognitive enhancement at its most fundamental level.[1] This positions it as one of the most mechanistically rational semax nootropic compounds in the research peptide space.

Beyond BDNF, semax activates dopaminergic and serotonergic neurotransmitter systems — the two pathways most directly associated with motivation, focus, mood regulation, and reward processing.[2] This dual neurotransmitter modulation, combined with neurotrophic factor upregulation, creates a multi-mechanism cognitive support profile. Crucially, despite being derived from ACTH, semax does not stimulate cortisol or activate the adrenal cortex — the hormonal segments responsible for ACTH’s stress-hormone effects are absent from the ACTH(4-10) fragment.

The second major research domain is semax neuroprotective activity. Preclinical studies demonstrate that semax activates neurotrophic gene transcription after cerebral ischemia — the oxygen-deprived conditions of stroke.[3] This neuroprotective profile has driven its clinical use in Russia for both cognitive support and ischemic stroke recovery. Semax operates through a fundamentally different mechanism than tissue-repair peptides like BPC-157 or TB-500, targeting neurotrophin expression rather than angiogenesis or inflammation.

How Semax Works

The pharmacological logic of semax begins with the structure of ACTH itself. Full-length ACTH (39 amino acids) drives cortisol production through the adrenal cortex — but the cognitive and neurotrophic effects reside specifically in the ACTH 4-10 fragment (positions 4 through 10 of the ACTH sequence). By isolating this fragment and discarding the N-terminal (1-3) and C-terminal (11-39) segments, semax retains the cognitive-active region while eliminating hormonal activity entirely. The C-terminal Pro-Gly-Pro extension was engineered to prevent rapid enzymatic degradation, extending the functional half-life of what would otherwise be a rapidly cleared peptide fragment.

Dolotov et al. (2006) demonstrated that semax regulates BDNF and TrkB expression in the rat hippocampus — providing direct evidence that the ACTH 4-10 fragment drives neurotrophic signalling in the brain region most critical for memory and learning.[1] Eremin et al. (2005) established that semax activates both dopaminergic and serotonergic brain systems in rodents, identifying the neurotransmitter pathways that complement its neurotrophic activity.[2] Dmitrieva et al. (2010) extended the mechanistic picture to neuroprotection, showing that semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia — demonstrating that the compound upregulates the brain’s own repair machinery in response to ischemic injury.[3]

This mechanism — neurotrophic factor upregulation combined with neurotransmitter system activation — is distinct from most other peptide mechanisms. Where growth hormone secretagogues like ipamorelin and GHRP-2 operate through the GH-IGF-1 axis, and tissue-repair peptides like TB-500 work through actin regulation, semax acts directly on central nervous system neurotrophin pathways.

Cognitive & Nootropic Support Context

The cognitive and nootropic support profile of semax is its primary research domain — and the area where the mechanistic evidence is strongest. BDNF upregulation is the central mechanism: brain-derived neurotrophic factor drives long-term potentiation (LTP), the cellular process underlying memory consolidation and learning. By increasing both BDNF and its receptor TrkB in the hippocampus, semax activates the molecular substrate of cognitive enhancement at a foundational level.[1]

Manchenko et al. (2010) characterised nootropic and analgesic effects of semax across different experimental paradigms, confirming cognitive performance improvements in preclinical models.[4] Panikratova et al. (2020) applied functional connectomic analysis to study semax’s effects on brain network organisation, providing neuroimaging-level evidence of altered functional connectivity consistent with enhanced cognitive processing.[5] The combined dopaminergic and serotonergic activation adds motivational and mood-regulatory dimensions to the cognitive profile — a multi-pathway nootropic mechanism that distinguishes semax from compounds acting on single neurotransmitter systems.

For context within the peptide landscape: most peptides studied for cognitive effects operate indirectly — through GH-mediated neuroprotection (sermorelin, CJC-1295) or through tissue-repair mechanisms with secondary neural benefits (BPC-157). Semax is unusual in targeting CNS neurotrophin pathways directly, making it one of the most mechanism-specific nootropic peptides in the current research landscape. The peptide epithalon provides an interesting parallel — while its mechanism (telomerase activation) is entirely different, it similarly targets a specific molecular pathway rather than operating through broad systemic effects.

Neuroprotection Context

The neuroprotection research on semax centres on its ability to activate the brain’s endogenous repair machinery after ischemic injury. Cerebral ischemia — the oxygen deprivation that occurs during stroke — triggers widespread neuronal death, and compounds that can upregulate neurotrophic gene expression during the critical post-ischemic window represent a significant research target. Dmitrieva et al. (2010) demonstrated that semax activates transcription of neurotrophins and their receptor genes after experimental cerebral ischemia, providing evidence for a direct neuroprotective mechanism.[3]

Filippenkov et al. (2024) advanced this research significantly, showing that ACTH-like peptides including semax can compensate for disrupted brain gene expression profiles following experimental stroke — essentially demonstrating that semax partially normalises the catastrophic transcriptomic changes caused by ischemia.[6] Glazova et al. (2021) extended semax’s neuroprotective profile to developmental neurotoxicity, showing that the compound attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure — suggesting neuroprotective relevance beyond acute ischemic injury.[7]

Most recently, Liu et al. (2025) identified a novel neuroprotective mechanism: semax targets the μ-opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury, opening a new mechanistic dimension beyond the established BDNF/neurotrophin pathway.[8] This expanding mechanistic profile — from BDNF upregulation to gene expression normalisation to opioid receptor modulation — suggests that semax neuroprotective effects may operate through multiple convergent pathways. For comparison, GHK-Cu has also shown neuroprotective potential through entirely different mechanisms (gene expression modulation and anti-inflammatory activity).

Semax Benefits

The semax benefits profile reflects its dual nootropic-neuroprotective mechanism, supported by both preclinical research and Russian clinical use:

• BDNF upregulation: Directly increases brain-derived neurotrophic factor and TrkB receptor expression in the hippocampus — the molecular foundation of synaptic plasticity and memory formation.[1]
• Neuroprotective in ischemia models: Activates neurotrophic gene transcription after cerebral ischemia, partially normalising gene expression disrupted by stroke.[3][6]
• Nootropic without hormonal effects: Retains the cognitive-active ACTH(4-10) fragment while eliminating adrenal cortex stimulation — cognitive enhancement without cortisol elevation.
• No cortisol stimulation: Despite being derived from ACTH, semax does not activate the HPA axis or stimulate cortisol release — a critical distinction from full-length ACTH.
• Dopamine and serotonin modulation: Activates both dopaminergic and serotonergic systems, supporting motivation, focus, and mood regulation.[2]
• Approved medication in Russia: Clinical approval since 2001 as a nootropic nasal spray provides a level of regulatory validation absent for most research peptides.
• Well-characterised mechanism: The ACTH-derived pharmacological rationale is well-understood, with multiple published mechanistic studies in English-language journals.[1][2][3]
• Expanding research profile: Recent studies continue to identify novel mechanisms including gene expression normalisation post-stroke and μ-opioid receptor modulation.[6][8]

Semax Side Effects

The semax side effects profile is generally favourable based on available data:

• Generally well-tolerated: Russian clinical experience since 2001 has not identified major safety concerns, supporting a favourable tolerability profile within the context of its approved use.
• No hormonal (adrenal) side effects: Unlike full-length ACTH, semax does not stimulate cortisol, aldosterone, or other adrenal hormones — the hormonal segments are absent from the ACTH(4-10) fragment.
• Nasal irritation: The most commonly noted effect with intranasal formulations — local irritation at the site of application, typically mild and transient.
• Limited Western safety data: Most safety characterisation derives from Russian clinical use rather than Western regulatory-grade safety studies. The absence of large-scale Western pharmacovigilance data is a limitation.
• Short duration of action: The short half-life means effects dissipate rapidly — a potential limitation for sustained cognitive support but also a safety advantage in terms of reversibility.

The semax side effects profile compares favourably to many GH-axis peptides that produce broader systemic effects. Unlike GHRP-6 or GHRP-2, which stimulate cortisol, appetite, and other hormonal pathways, semax’s CNS-targeted mechanism produces a narrower and generally milder side effect profile. The principal caveat is not the presence of known side effects but the absence of comprehensive Western safety data.

Half-Life

Semax has a short plasma half-life measured in minutes — characteristic of small peptide fragments that are rapidly cleared by circulating peptidases. However, the C-terminal Pro-Gly-Pro extension was specifically engineered to improve metabolic stability compared to the native ACTH(4-10) fragment, which would otherwise be degraded within seconds to minutes. This stabilisation strategy is pharmacologically analogous to how CJC-1295 uses Drug Affinity Complex (DAC) technology to extend the half-life of GHRH analogs, though the mechanisms differ.

The short circulating half-life does not necessarily limit functional duration: semax’s downstream effects — BDNF upregulation, neurotrophic gene transcription, neurotransmitter system modulation — operate on longer biological timescales than the peptide’s plasma presence. This is consistent with the principle that many peptide signalling molecules act as triggers rather than sustained effectors, initiating cascades that persist beyond the compound’s circulating presence. For comparison across peptide half-lives: ipamorelin has approximately a 2-hour half-life, sermorelin is 10-20 minutes, and epithalon operates on similarly short timescales with longer-duration downstream effects.

Limits of Current Evidence

• Not FDA or EMA approved: Semax has no regulatory approval outside Russia and former Soviet states. Unlike semaglutide and liraglutide (FDA-approved GLP-1 agonists) or tesamorelin (FDA-approved GHRH analog), semax lacks Western regulatory validation.
• Russian clinical approval provides some validation: Approval since 2001 as a nootropic nasal spray represents real regulatory review, but Russian approval standards differ from FDA/EMA requirements and may not satisfy Western evidence thresholds.
• More English-language data than many Russian-developed peptides: Semax has a growing body of English-language mechanistic publications, but still limited large-scale Western clinical trial data. Most human outcome data exists in Russian-language literature.
• Strong preclinical data, limited clinical translation: Animal model data for ischemia, BDNF upregulation, and behavioural effects is robust, but human outcome trials in Western literature are scarce. The gap between preclinical promise and clinical validation remains significant.
• Well-understood ACTH-derived mechanism provides confidence: The pharmacological rationale — isolating the cognitive-active ACTH(4-10) fragment — is grounded in well-established ACTH biology, which provides mechanistic confidence even where clinical data is limited.
• Long-term safety data is limited to Russian pharmacovigilance: Multi-year safety profiles from Western regulatory-grade monitoring do not exist.

Verdict

Semax is one of the most pharmacologically rational nootropic peptides in the research landscape. By isolating the cognitive-active ACTH 4-10 fragment — the region of adrenocorticotropic hormone responsible for neurotrophic and nootropic effects — and stabilising it with a Pro-Gly-Pro C-terminal extension, the semax peptide achieves targeted neurotrophic and neuroprotective activity without hormonal cross-talk. The semax BDNF upregulation data is compelling and mechanistically well-characterised, and its activation of dopaminergic and serotonergic systems provides a multi-pathway cognitive support profile.[1][2]

The Russian clinical approval since 2001 adds a layer of regulatory weight that most research peptides lack entirely — this is a compound that has been prescribed and monitored in clinical settings for over two decades, not merely studied in laboratory conditions. The expanding English-language research base — from BDNF upregulation to post-ischemic gene expression normalisation to spinal cord injury recovery — demonstrates a compound with a deepening rather than narrowing evidence profile.[3][6][8]

This semax review of the published evidence makes the limitation clear: outside Russia, semax remains investigational. The absence of FDA/EMA approval and large-scale Western clinical trials means that international regulatory frameworks do not recognise its efficacy claims. For researchers and clinicians evaluating nootropic peptides, semax presents a compound where the mechanistic rationale is strong, the Russian clinical experience is extensive, but the Western evidentiary standard has not yet been met. This positions it as one of the most interesting compounds to watch as the English-language evidence base continues to develop. The semax vs selank comparison is particularly instructive: both are Russian-developed nootropic peptides from the same institute, but semax targets BDNF/neurotrophin pathways while selank targets anxiolytic/immunomodulatory pathways — complementary rather than competing mechanisms.

FAQ

What is Semax?

Semax is a synthetic heptapeptide analog of ACTH(4-10) — the fragment of adrenocorticotropic hormone responsible for cognitive and neurotrophic effects. It was developed at the Institute of Molecular Genetics, Russian Academy of Sciences, and has been approved in Russia since 2001 as a nootropic and neuroprotective nasal spray. It is not approved by the FDA or EMA.

Is Semax the same as ACTH?

No. Semax contains only the ACTH(4-10) fragment — seven amino acids from the cognitive-active region of the 39-amino-acid ACTH molecule. The segments responsible for adrenal cortex stimulation and cortisol production (positions 1-3 and 11-39) are absent. Semax retains nootropic and neurotrophic effects while eliminating hormonal activity.[1]

Does Semax increase cortisol?

No. Despite being derived from ACTH (which is the primary driver of cortisol production), semax does not stimulate the adrenal cortex or increase cortisol levels. The ACTH(4-10) fragment lacks the structural elements required for adrenal activation — this separation of cognitive from hormonal effects is the core pharmacological design principle of semax.

What is the difference between Semax and Selank?

Both are synthetic heptapeptides developed at the same Russian institute (Institute of Molecular Genetics, RAS) and approved in Russia as nasal sprays. However, they target different mechanisms: semax is an ACTH(4-10) analog that upregulates BDNF and activates dopaminergic/serotonergic systems for nootropic and neuroprotective effects. Selank is a tuftsin analog that modulates enkephalin metabolism for anxiolytic and immunomodulatory effects. They are complementary rather than interchangeable compounds.

Is Semax approved anywhere?

Yes. Semax has been approved in Russia since 2001 as a nootropic and neuroprotective nasal spray. It is not approved by the FDA, EMA, or other Western regulatory agencies. It is not classified as a controlled substance internationally.

Does Semax increase BDNF?

Yes. Dolotov et al. (2006) demonstrated that semax regulates BDNF and TrkB receptor expression in the rat hippocampus — providing direct evidence of neurotrophic factor upregulation. BDNF upregulation is considered the primary mechanistic basis of semax’s nootropic and neuroprotective effects.[1]

Is Semax FDA approved?

No. Semax is not FDA-approved for any indication. It remains a research compound in Western regulatory contexts. Its only regulatory approval is in Russia, where it has been an approved medication since 2001. For FDA-approved peptide-class therapeutics, see semaglutide, liraglutide, or tesamorelin.

References

1. Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PMID: 16996037
2. Eremin KO, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. PMID: 16362768
3. Dmitrieva VG, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(1):71-79. PMID: 19633950
4. Manchenko DM, et al. Nootropic and analgesic effects of Semax following different routes of administration. Ross Fiziol Zh. 2010;96(10):1014-1023. PMID: 21268834
5. Panikratova YR, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020;490(1):9-11. PMID: 32342318
6. Filippenkov IB, et al. ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke. Biomedicines. 2024;13(1):18. PMID: 39767736
7. Glazova NY, et al. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure. Neuropeptides. 2021;86:102117. PMID: 33418449
8. Liu R, et al. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury. Br J Pharmacol. 2025;182(22). PMID: 40692165

Medical Disclaimer: This page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Semax is not approved by the FDA for any indication. Always consult a qualified healthcare professional before making any decisions related to your health. The information presented reflects published research and does not imply endorsement of any compound for human use outside of supervised clinical settings.